Local DHEA and Estradiol on Dyspareunia in Postmenopausal Women

PHASE4CompletedINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

December 15, 2024

Study Completion Date

December 15, 2024

Conditions

Vulvovaginal AtrophyGenitourinary Syndrome of Menopause

Interventions

DRUG

vaginal estradiol 10 μg

Vagifem® (estradiol), vaginal tablets

DRUG

vaginal DHEA 6.5 mg

Intrarosa® (dehydroepiandrosterone; DHEA; prasterone), pessaries

Trial Locations (1)

Karolinska University Hospital, Stockholm

All Listed Sponsors

lead

Angelica Lindén Hirschberg

OTHER

NCT05586711 - Local DHEA and Estradiol on Dyspareunia in Postmenopausal Women | Biotech Hunter | Biotech Hunter